Safety profle of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

• Eva Ciruelos ^[1] ; Jose Ángel García Sáenz ^[2] ; Joaquín Gavilá ^[3] ; Miguel Martín ^[4] ; César A. Rodríguez ^[6] ; Álvaro Rodríguez Lescure ^[5]
  1. [1] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  2. [2] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  3. [3] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  4. [4] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  5. [5] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  6. [6] Medical Oncology Unit, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 7, 2024, págs. 1539-1548
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Trastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate that targets human epidermal growth factor receptor 2(HER2) and has shown promising results in the treatment of advanced/metastatic breast cancer. The objective of this report isto provide guidance on the prophylaxis, monitoring, and management of adverse events (AEs) in patients with breast cancer treated with T-DXd, and to emphasize that proper management of AEs is needed to optimize the efectiveness of T-DXd treatment and reduce the number of discontinuations. The article covers various aspects of T-DXd treatment, including its clinical efcacy, safety profle, and dosing considerations, and provides practical recommendations for managing AEs, such as nausea/vomiting, interstitial lung disease, and hematologic toxicity. Although there are still many knowledge gaps about the cause and incidence of AEs in real-world patients, this document may serve as a valuable resource for clinicians who are involved in the care of breast cancer patients receiving T-DXd treatment.